"$MRK concerned about dominant positioning of Keytruda monotherapy in PD-L1 high patients-they emphasized there is still some room for further activity for novel agents in combo with PD-1 antibodies, think there's still a lot of wood to chop before TIGIT meaningful competitor"
totally agree and love this comment. Combining two IO therapeutics is asking way too much for an immune response to most cancers. IO therapies need to be combined with therapies that directly target tumors. been saying this for years and now the data is coming in....